Journal Information
Vol. 41. Issue. 6.November - December 2021
Pages 605-712
Vol. 41. Issue. 6.November - December 2021
Pages 605-712
Letter to the Editor
Open Access
Use HFR-supra for inflammatory bowel disease: A case report
Uso de HFR-supra en la enfermedad inflamatoria intestinal: a propósito de un caso en hemodiálisis crónica
Tania Monzóna,
Corresponding author

Corresponding author.
, Francisco Valgab, Fernando Henríqueza, Francisco Alonsoa, Yanet Parodisa, Sebastian Hillebranda, Gloria Antón Péreza
a Servicio de Nefrología, Centro de Hemodiálisis Avericum Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain
b Servicio de Nefrología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Download PDF
Tables (1)
Table 1. Inflammatory parameters during the three stages of the patient's treatment.
Full Text
Dear Editor,

We present the case of a 33-year-old patient, diagnosed in 2011 with inflammatory bowel disease (Crohn's disease). He presents ileocolitis with torpid evolution, corticodependence and failure of multiple treatments (azathioprine, methotrexate and adalimumab) due to side effects. It is associated to complex perianal requiring drainage of a perianal abscess and follow-up of general surgery.

In December 2014, he was admitted due to progressive swelling, proteinuria of 500mg/dl, hypoproteinemia of 6g/dl, and hypoalbuminaemia of 2.3g/dl. Initially he maintained normal renal function but it deteriorates gradually until Cr 1.7mg/dl. A kidney biopsy was performed with a diagnosis of secondary renal amyloidosis (AA), with intense tubulointerstitial fibrosis. Given these findings, he received 3 boluses of methylprednisolone (500mg) along with the start of monthly infliximab, but again he presented poor tolerance to treatment with biological therapy, and it has to be suspended. The patient remains asymptomatic from 2015 until the beginning of 2020 when he was admitted due to an exacerbation of his chronic kidney disease, with a negative autoimmune study and abdominal ultrasound compatible with chronic nephropathy. During admission the serum creatinine was of 11mg/dl (estimated GFR by CKD-EPI, 5mgml/min/1.73m2), nephrotic range proteinuria 4g/24h, along with hyperphosphatemia, hyperuricemia, metabolic acidosis, and anemia. With a previous diagnosis of secondary amyloidosis (AA), it was decided to start renal replacement therapy with hemodialysis (HD) through a right jugular tunneled CVC in February 2020.

Given the characteristics of his underlying disease, 2 months later it was decided to start HFR-supra with the idea of controlling the inflammatory state associated with the patient's underlying disease.

We decided to retrospectively evaluate the inflammatory status of the patient during 3 periods (before the start of HD, with conventional HD and after 2 months of HFR-supra) to assess the efficacy of the treatment both clinically and analytically. CRP, ferritin, INL and IPL were measured as markers of general inflammation and calprotectin as a marker of intestinal inflammatory activity (Table 1).

Table 1.

Inflammatory parameters during the three stages of the patient's treatment.

  Pre-HD  Home HD conventional  HFR-supra 
Calprotectin; mg/kg  >1000  No data  25.8 
PCR; mg/l  1.95  1.75  1.7 
NLI  1.42  1.97  2.17 
PLI  62.35  106.25  102.01 
Ferritin; ng/ml  557  412.3  247 

HD: hemodialysis; NLI: neutrophil/lymphocyte index; IPL: platelet/lymphocyte index; CRP: C-reactive protein.

Since the change in technique, he has not presented a recurrence of his disease (currently under treatment with colchicine that has not changed), the frequency and characteristics of bowel movements and episodes of pain improved.

Inflammatory bowel disease includes Crohn's disease and ulcerative colitis. They are intestinal diseases characterized by being immune-mediated, with inflammatory activity and of a chronic evolution with flare-ups and alternating with recurrent periods of remission.

The HFR-supra technique combines convention, adsorption, and diffusion. Currently, there are multiple studies that show good results in multiple myeloma,1 in the control of inflammatory markers due to a decrease in pro-inflammatory cytokines, NOS, IL-6 and p-Cresol2–4 and has even shown to be useful in diseases such as porphyria cutaneous tarda.5

Our case explores the usefulness of the technique in systemic diseases with a predominance of inflammation at a local intestinal level. However, clinical trials are needed to confirm this effect. As in other isolated case publications,5 our hypothesis is based on the fact that this technique could eliminate the inflammatory molecules derived from the secondary oxidative stress of the disease itself, with the consequent improvement of the patient's symptoms.

M.V. Pendón-Ruiz de Mier, M.A. Alvarez-Lara, R. Ojeda-López, A. Martín-Malo, J. Carracedo, J. Caballero-Villarraso, et al.
Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
E. Riccio, M. Cataldi, M. Minco, G. Argentino, R. Russo, S. Brancaccio, et al.
Evidence that p-cresol and IL-6 are adsorbed by the HFR cartridge: towards a new strategy to decrease systemic inflammation in dialyzed patients?.
B. González-Diez, M. Cavia, G. Torres, P. Abaigar, V. Camarero, P. Muñiz.
The effects of 1-year treatment with a haemodiafiltration with on-line regeneration of ultrafiltrate (HFR) dialysis on biomarkers of oxidative stress in patients with chronic renal failure.
Mol Biol Rep, 39 (2012), pp. 629-634
L.A. Calò, A. Naso, P.A. Davis, E. Pagnin, R. Corradini, A. Tommasi, et al.
Hemodiafiltration with online regeneration of ultrafiltrate: effect on heme-oxygenase-1 and inducible subunit of nitric oxide synthase and implication for oxidative stress and inflammation.
Artif Organs, 35 (2011), pp. 183-187
T. Monzón, Y. Parodis, F. Valga, F. Henríquez, G. Antón Pérez.
Use HFR-supra for porphyria cutanea tarda treatment in hemodialysis patient. Uso de HFR-supra para el tratamiento de porfiria cutánea tarda en paciente en hemodiálisis crónica.
Nefrologia, 39 (2019), pp. 216-218

Please cite this article as: Monzón T, Valga F, Henríquez F, Alonso F, Parodis Y, Hillebrand S, et al. Uso de HFR-supra en la enfermedad inflamatoria intestinal: a propósito de un caso en hemodiálisis crónica. Nefrologia. 2022;41:710–711.

Nefrología (English Edition)
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?